The SmartTouch for Symbicort is a monitoring device that is installed onto the patient's inhaler to track and improve medication adherence. The Food and Drug Administration (FDA) has granted Adherium ...
The Food and Drug Administration (FDA) has cleared the Propeller Health digital platform to connect with the Symbicort® Inhaler (budesonide, formoterol fumarate dihydrate; AstraZeneca), a ...
Smart inhaler company Adherium announced last week that it has received 510(k) clearance for over-the-counter sales of its inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler, called ...
With a new clearance from the FDA, smart inhaler developer Propeller Health is bringing its connected platform to AstraZeneca’s Symbicort to help digitize the treatment of asthma and chronic ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) today announced the publication of data demonstrating that SYMBICORT Inhalation Aerosol 320/9 µg twice daily had a safety profile similar to ...
DENVER--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) today announced results from a long-term study comparing SYMBICORT ® (budesonide/ formoterol fumarate dihydrate) Inhalation Aerosol 160/4.5 mcg with ...
(RTTNews) - The U.S. Food and Drug Administration approved Mylan Pharmaceuticals, Inc.'s generic of Symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol. It is the first FDA- ...
AstraZeneca Announces Symbicort Is Now Available In The U.S. U.S. Asthma Sufferers Now Have a New Choice of Combination Therapy to Help Achieve Asthma Control LONDON ...
Wilmington, DE – June 4, 2008 – AstraZeneca (NYSE: AZN) today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...
Full approval by the FDA follows tentative approval for the complex drug delivery advice for asthma and chronic obstructive pulmonary disease (COPD) granted by the FDA last week amid a patent dispute.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results